Physician profile
Michael S Levine
NPI 1154305191
$20,716.80
in general payments reported to CMS, 2019-2025
40 companies · $1,826 in 2025
The $1,826 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,109 · 2020: $1,192 · 2021: $1,816 · 2022: $1,939 · 2023: $4,127 · 2024: $1,708 · 2025: $1,826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,066 · Consulting Fee: $1,563 · Education: $31.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,066.25 |
| Consulting Fee | $1,562.50 |
| Education | $31.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $6,534.75 | 2019-2020 | |
| Abbvie INC. | $3,499.29 | 2019-2025 | |
| Ardelyx, INC. | $1,826.70 | 2022-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,511.82 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $766.19 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $755.09 | 2020-2025 | Stelara, Tremfya, Simponi |
| Pfizer INC. | $594.76 | 2019-2025 | |
| Genzyme Corporation | $593.14 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $514.54 | 2019-2024 | Ocaliva |
| Janssen Scientific Affairs, LLC | $503.40 | 2019-2025 | Tremfya, Stelara |
| Regeneron Healthcare Solutions, INC. | $487.44 | 2022-2025 | Dupixent |
| Gilead Sciences, INC. | $440.86 | 2019-2025 | Epclusa, Livdelzi |
| Madrigal Pharmaceuticals | $271.89 | 2024-2025 | Rezdiffra |
| Lilly USA, LLC | $254.19 | 2023-2025 | Omvoh |
| Mallinckrodt Hospital Products INC. | $233.36 | 2024-2025 | Terlivaz |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $231.95 | 2023-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $229.09 | 2024-2025 | Zenpep, Vowst |
| Celgene Corporation | $226.88 | 2021-2024 | Zeposia |
| Romark Laboratories, Lc | $219.27 | 2019-2020 | |
| Medtronic, INC. | $119.20 | 2022 | |
| Ironwood Pharmaceuticals, INC | $115.71 | 2019-2022 | |
| Ucb, INC. | $109.46 | 2019-2020 | |
| Dova Pharmaceuticals | $95.71 | 2019 | |
| Merck Sharp & Dohme LLC | $82.50 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $81.93 | 2024-2025 | Voquezna |
| Redhill Biopharma INC. | $58.46 | 2020-2022 | |
| Alfasigma USA, INC. | $54.49 | 2020 | |
| Qol Medical, LLC | $41.07 | 2023-2024 | Sucraid, Sucraid |
| Ferring Pharmaceuticals INC. | $38.74 | 2021-2023 | Rebyota |
| Amgen INC. | $36.92 | 2023 | Avsola, Amjevita |
| Celltrion USA INC. | $31.92 | 2023-2024 | Yuflyma, Zymfentra |
| Novo Nordisk INC | $29.18 | 2025 | Wegovy |
| Daiichi Sankyo INC. | $24.14 | 2021 | |
| Braintree Laboratories, INC. | $21.78 | 2024 | Suflave, Sutab |
| Organon LLC | $18.03 | 2025 | Hadlima, Renflexis |
| Nestle Healthcare Nutrition INC. | $17.68 | 2022 | |
| Alnylam Pharmaceuticals INC. | $16.23 | 2022 | |
| Alexion Pharmaceuticals, INC. | $14.90 | 2022 | |
| Ethicon US, LLC | $14.14 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.